Ryan H. Saadi Sells 1,438,206 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Stock

Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) CEO Ryan H. Saadi sold 1,438,206 shares of the business's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $1.23, for a total value of $1,768,993.38. Following the transaction, the chief executive officer now directly owns 116,814,453 shares of the company's stock, valued at approximately $143,681,777.19. This represents a 1.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Tevogen Bio Price Performance

Shares of Tevogen Bio stock traded down $0.07 on Thursday, hitting $1.27. The company's stock had a trading volume of 586,287 shares, compared to its average volume of 5,049,989. The firm has a fifty day moving average price of $1.13 and a 200-day moving average price of $1.20. Tevogen Bio Holdings Inc. has a 52-week low of $0.26 and a 52-week high of $3.09.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital reiterated a "buy" rating and issued a $10.00 price target on shares of Tevogen Bio in a research report on Tuesday.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its position in Tevogen Bio by 31.2% during the fourth quarter. Geode Capital Management LLC now owns 451,851 shares of the company's stock worth $465,000 after buying an additional 107,566 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Tevogen Bio by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company's stock valued at $122,000 after acquiring an additional 13,595 shares during the last quarter. Nuveen LLC purchased a new stake in Tevogen Bio during the 1st quarter worth about $97,000. XTX Topco Ltd purchased a new stake in Tevogen Bio during the 4th quarter worth about $55,000. Finally, Barclays PLC raised its stake in Tevogen Bio by 39.2% in the 4th quarter. Barclays PLC now owns 45,600 shares of the company's stock valued at $48,000 after purchasing an additional 12,847 shares during the last quarter.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.